Levorphanol Tartrate Injection Levorphanol Tartrate

Levorphanol Tartrate Injection Levorphanol Tartrate

4104 Levonorgestrel / Official Monographs USP 36 Column: 4-mm × 15-cm; packing L7 IdentificationÐ Flow rate: 1 mL/min A: Infrared Absorption 〈197K〉ÐObtain the test specimen Injection size: 100 µL as follows. Dissolve 50 mg in 25 mL of water in a 125-mL System suitability separator. Add 2 mL of 6 N ammonium hydroxide, extract Sample: Standard solution with 25 mL of chloroform, and filter the chloroform extract [NOTEÐThe relative retention times for ethinyl estradiol through a layer of 4 g of granular anhydrous sodium sulfate and levonorgestrel are about 0.7 and 1.0, supported on glass wool into a 125-mL conical flask. Evapo- respectively.] rate the chloroform extract on a steam bath with the aid of Suitability requirements a stream of nitrogen to dryness. Dissolve the residue in 1 mL Relative standard deviation: NMT 3.0% of acetone, and evaporate to dryness. Dry in vacuum at 90° Analysis for 1 hour. Proceed as directed with the dried levorphanol Samples: Standard solution and Sample solution so obtained and a similar preparation of USP Levorphanol Calculate the percentage of C21H28O2 and C20H24O2 Tartrate RS. dissolved: B: Ultraviolet Absorption 〈197U〉Ð Result = (rU/rS) × (CS/CU) × 100 Solution: 130 µg per mL. Medium: 0.1 N hydrochloric acid. rU = peak response of the corresponding analyte Absorptivities at 279 nm, calculated on the anhydrous ba- from the Sample solution sis, do not differ by more than 3.0%. rS = peak response of the corresponding analyte Specific rotation 〈781S〉: between −14.7° and −16.3°. from the Standard solution Test solution: 30 mg per mL, in water. Heat on a water CS = concentration of the appropriate USP Reference Standard in the Standard solution bath or sonicate to dissolve 750 mg in 20 mL of water in a (µg/mL) 25-mL volumetric flask, dilute with water to volume, and mix. CU = nominal concentration of the corresponding analyte in the Sample solution (µg/mL) Water, Method I 〈921〉: between 7.0% and 9.0%. Tolerances Residue on ignition 〈281〉: not more than 0.1%. Uncoated Tablets: NLT 80% (Q) of the labeled Ordinary impurities 〈466〉Ð amount of C21H28O2, and 75% (Q) of the labeled Test solution: water. amount of C20H24O2 is dissolved. Coated Tablets: NLT 60% (Q) of the labeled amount Standard solution: water. of C21H28O2 and C20H24O2 is dissolved. Eluant: a mixture of hexanes, dehydrated alcohol, and • UNIFORMITY OF DOSAGE UNITS 〈905〉: Meet the ammonium hydroxide (80:25:1). requirements Visualization: 17; then view immediately under short- Sample solution: Place 1 Tablet in a 40-mL centrifuge wavelength UV light. tube, add 10.0 mL of Mobile phase, and proceed as di- AssayÐDissolve about 900 mg of sample, accurately rected in the Assay. weighed, in 85 mL of glacial acetic acid, warming slightly if ADDITIONAL REQUIREMENTS necessary. Titrate with 0.1 N perchloric acid VS and deter- mine the endpoint potentiometrically. Perform a blank de- • PACKAGING AND STORAGE: Preserve in well-closed containers. termination and make any nececssary corrections. Each mL of 0.1 N perchloric acid consumed by the sample is equiva- • USP REFERENCE STANDARDS 〈11〉 USP Ethinyl Estradiol RS lent to 40.75 mg of C17H23NO ´ C4H6O6. USP Levonorgestrel RS . Levorphanol Tartrate Injection . Levorphanol Tartrate » Levorphanol Tartrate Injection is a sterile solu- tion of Levorphanol Tartrate in Water for Injec- tion. It contains not less than 93.0 percent and not more than 107.0 percent of the labeled amount of C17H23NO.C4H6O6 ´ 2H2O. Packaging and storageÐPreserve in single-dose or in C17H23NO ´ C4H6O6 ´ 2H2O 443.49 multiple-dose containers, preferably of Type I glass. Morphinan-3-ol, 17-methyl-, [R-(R*,R*)]-2,3-dihydroxy- USP Reference standards 〈11〉Ð butanedioate (1:1) (salt), dihydrate. USP Endotoxin RS 17-Methylmorphinan-3-ol, tartrate (1:1) (salt) dihydrate IdentificationÐ [5985-38-6]. Anhydrous 407.47 [125-72-4]. A: To 1 mL of Injection add 1 drop of 3 N hydrochloric acid and 2 drops of ferric chloride TS. Heat to boiling, and » Levorphanol Tartrate contains not less than add 1 mL of potassium ferricyanide solution (1 in 200): a 99.0 percent and not more than 101.0 percent of blue-green color develops. B: The angular rotation of the Injection is levorotatory C17H23NO ´ C4H6O6, calculated on the anhydrous basis. (see Optical Rotation 〈781〉). Bacterial endotoxins 〈85〉ÐIt contains not more than Packaging and storageÐPreserve in well-closed contain- 125.0 USP Endotoxin Units per mg of levorphanol tartrate. ers. Store at 25°, excursions permitted between 15° and pH 〈791〉: between 4.1 and 4.5. 30°. Other requirementsÐIt meets the requirements under In- USP Reference standards 〈11〉Ð jections 〈1〉. USP Levorphanol Tartrate RS USP 36 Official Monographs / Levothyroxine 4105 AssayÐTransfer an accurately measured volume of Injec- of USP Levorphanol Tartrate RS in the same medium having tion, equivalent to about 40 mg of levorphanol tartrate, to a a known concentration of about 80 µg of anhydrous 125-mL separator. Add 5 g of sodium chloride and sufficient levorphanol tartrate per mL, in 1-cm cells at the wavelength sodium bicarbonate to render the solution alkaline to litmus, of maximum absorbance at about 279 nm, with a suitable add an additional 100 mg of sodium bicarbonate, and ex- spectrophotometer, using 0.1 N hydrochloric acid as the tract the levorphanol with five 20-mL portions of a mixture blank. Calculate the quantity, in mg, of C17H23NO ´ C4H6O6 ´ of 3 volumes of ether and 1 volume of chloroform. Pass the 2H2O in the Tablet taken by the formula: combined extracts through a layer of about 10 g of granular anhydrous sodium sulfate into a 500-mL conical flask, and (443.49 / 407.47)(TC / D)(AU / AS) evaporate to a volume of about 30 mL. Add about 50 mL of chloroform and 1 drop of methanolic methyl red TS, and in which 443.49 and 407.47 are the molecular weights of titrate with 0.01 N perchloric acid in dioxane VS to a red the hydrated and anhydrous forms of levorphanol tartrate, endpoint. Perform a blank determination, and make any respectively; T is the labeled quantity, in mg, of levorphanol necessary correction. Each mL of 0.01 N perchloric acid is tartrate in the Tablet; C is the concentration, in µg per mL, equivalent to 4.435 mg of C17H23NO ´ C4H6O6 ´ 2H2O. of USP Levorphanol Tartrate RS, on the anhydrous basis, in the Standard solution; D is the concentration, in µg per mL, of levorphanol tartrate in the solution from the Tablet, based on the labeled quantity per Tablet and the extent of dilution; and AU and AS are the absorbances of the solution . Levorphanol Tartrate Tablets from the Tablet and the Standard solution, respectively. AssayÐWeigh and finely powder not less than 20 Tablets. Weigh accurately a portion of the powder, equivalent to » Levorphanol Tartrate Tablets contain not less about 40 mg of levorphanol tartrate, transfer to a 125-mL than 93.0 percent and not more than 107.0 per- separator, add 20 mL of water and sufficient sodium bicar- cent of the labeled amount of levorphanol tar- bonate to render the suspension alkaline to litmus, and pro- trate (C17H23NO ´ C4H6O6 ´ 2H2O). ceed as directed in the Assay under Levorphanol Tartrate In- jection, beginning with ªadd an additional 100 mg of Packaging and storageÐPreserve in well-closed contain- sodium bicarbonate.º ers. USP Reference standards 〈11〉Ð USP Levorphanol Tartrate RS . IdentificationÐ Levothyroxine Sodium A: Powder finely a number of Tablets. To a portion of the powder, equivalent to about 1 mg of levorphanol tartrate, add 1 mL of water, 1 drop of 3 N hydrochloric acid, and 2 drops of ferric chloride TS, and heat to boiling. To the hot solution add 1 mL of potassium ferricyanide solution (1 in 200): a bluish color develops. B: Powder a number of Tablets, equivalent to about 60 mg of levorphanol tartrate, and transfer the mixture to a C15H10I4NNaO4 ´ xH2O (anhydrous) 798.85 small separator. Add 10 mL of water, dissolve as much of L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, the powder as possible, add about 400 mg of sodium bicar- monosodium salt, hydrate; bonate, and extract with a 50-mL portion of chloroform. Monosodium L-thyroxine hydrate [25416-65-3]. Evaporate the filtered chloroform extract on a steam bath to Anhydrous [55-03-8]. a small volume, dilute with chloroform to 10 mL, and deter- mine the angular rotation: the solution is levorotatory (see DEFINITION Optical Rotation 〈781〉). Levothyroxine Sodium is the sodium salt of L-3,3′,5,5′-te- Dissolution 〈711〉Ð traiodothyronine. It contains NLT 97.0% and NMT Medium: water; 500 mL. 103.0% of levothyroxine sodium (C15H10I4NNaO4), calcu- lated on the anhydrous basis. Apparatus 2: 50 rpm. Time: 30 minutes. IDENTIFICATION ProcedureÐDetermine the amount of C17H23NO ´ C4H6O6 ´ 2H2O dissolved from UV absorbances at the wavelength of Change to read: maximum absorbance at about 279 nm on filtered portions of the solution under test, suitably diluted with water, in • A. LINFRARED ABSORPTION 〈197〉: [NOTEÐMethods de- comparison with a Standard solution having a known con- scribed in Infrared Absorption 〈197K〉 or 〈197A〉 may be centration of USP Levorphanol Tartrate RS in the same me- used.]LUSP36 dium. TolerancesÐNot less than 75% (Q) of the labeled amount Delete the following: of C17H23NO ´ C4H6O6 ´ 2H2O is dissolved in 30 minutes. Uniformity of dosage units 〈905〉: meet the require- L ments. • B. Acid sodium chloride solution: Alcohol, 1 N sodium hy- Procedure for content uniformityÐTransfer 1 Tablet to a droxide, hydrochloric acid, and water (25:10:10:30) glass-stoppered flask, add 25.0 mL of 0.1 N hydrochloric Sample: 0.5 mg acid, and allow the Tablet to disintegrate.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    2 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us